Selected research
Industry Research
Radioisotopes in Medicine Industry Research Report 2026
Market perspective
The global Radioisotopes in Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Radioisotopes in Medicine is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Radioisotopes in Medicine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Radioisotopes in Medicine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Radioisotopes in Medicine include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Radioisotopes in Medicine market in revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Radioisotopes in Medicine.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Radioisotopes in Medicine Market by Company
ANSTO
China National Nuclear Corporation
Eckert & Ziegler Strahlen
IRE
Nordion
NorthStar Medical Radioisotopes
NRG
NTP Radioisotopes
Polatom
Rosatom
SHINE Technologies
Radioisotopes in Medicine Segment by Type
Tc-99m
Iodine Radioisotopes
Cobalt-60
Others
Radioisotopes in Medicine Segment by Application
Nuclear Therapy
Equipment Radioactive Source
Diagnosis
Radioisotopes in Medicine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radioisotopes in Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radioisotopes in Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radioisotopes in Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Radioisotopes in Medicine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Radioisotopes in Medicine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Radioisotopes in Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tc-99m
- Iodine Radioisotopes
- Cobalt-60
- Others
Applications
- Nuclear Therapy
- Equipment Radioactive Source
- Diagnosis
Companies covered
- ANSTO
- China National Nuclear Corporation
- Eckert & Ziegler Strahlen
- IRE
- Nordion
- NorthStar Medical Radioisotopes
- NRG
- NTP Radioisotopes
- Polatom
- Rosatom
- SHINE Technologies
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Radioisotopes in Medicine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Tc-99m
- 2.2.3 Iodine Radioisotopes
- 2.2.4 Cobalt-60
- 2.2.5 Others
- 2.3 Radioisotopes in Medicine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nuclear Therapy
- 2.3.3 Equipment Radioactive Source
- 2.3.4 Diagnosis
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Radioisotopes in Medicine Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Radioisotopes in Medicine Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Radioisotopes in Medicine Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Radioisotopes in Medicine Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Radioisotopes in Medicine Production by Manufacturers (2021-2026)
- 3.2 Global Radioisotopes in Medicine Production Value by Manufacturers (2021-2026)
- 3.3 Global Radioisotopes in Medicine Average Price by Manufacturers (2021-2026)
- 3.4 Global Radioisotopes in Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Radioisotopes in Medicine Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Radioisotopes in Medicine Manufacturers, Product Type & Application
- 3.7 Global Radioisotopes in Medicine Manufacturers Established Date
- 3.8 Global Radioisotopes in Medicine Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ANSTO
- 4.1.1 ANSTO Radioisotopes in Medicine Company Information
- 4.1.2 ANSTO Radioisotopes in Medicine Business Overview
- 4.1.3 ANSTO Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 ANSTO Product Portfolio
- 4.1.5 ANSTO Recent Developments
- 4.2 China National Nuclear Corporation
- 4.2.1 China National Nuclear Corporation Radioisotopes in Medicine Company Information
- 4.2.2 China National Nuclear Corporation Radioisotopes in Medicine Business Overview
- 4.2.3 China National Nuclear Corporation Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 China National Nuclear Corporation Product Portfolio
- 4.2.5 China National Nuclear Corporation Recent Developments
- 4.3 Eckert & Ziegler Strahlen
- 4.3.1 Eckert & Ziegler Strahlen Radioisotopes in Medicine Company Information
- 4.3.2 Eckert & Ziegler Strahlen Radioisotopes in Medicine Business Overview
- 4.3.3 Eckert & Ziegler Strahlen Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Eckert & Ziegler Strahlen Product Portfolio
- 4.3.5 Eckert & Ziegler Strahlen Recent Developments
- 4.4 IRE
- 4.4.1 IRE Radioisotopes in Medicine Company Information
- 4.4.2 IRE Radioisotopes in Medicine Business Overview
- 4.4.3 IRE Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 IRE Product Portfolio
- 4.4.5 IRE Recent Developments
- 4.5 Nordion
- 4.5.1 Nordion Radioisotopes in Medicine Company Information
- 4.5.2 Nordion Radioisotopes in Medicine Business Overview
- 4.5.3 Nordion Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 Nordion Product Portfolio
- 4.5.5 Nordion Recent Developments
- 4.6 NorthStar Medical Radioisotopes
- 4.6.1 NorthStar Medical Radioisotopes Radioisotopes in Medicine Company Information
- 4.6.2 NorthStar Medical Radioisotopes Radioisotopes in Medicine Business Overview
- 4.6.3 NorthStar Medical Radioisotopes Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 NorthStar Medical Radioisotopes Product Portfolio
- 4.6.5 NorthStar Medical Radioisotopes Recent Developments
- 4.7 NRG
- 4.7.1 NRG Radioisotopes in Medicine Company Information
- 4.7.2 NRG Radioisotopes in Medicine Business Overview
- 4.7.3 NRG Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 NRG Product Portfolio
- 4.7.5 NRG Recent Developments
- 4.8 NTP Radioisotopes
- 4.8.1 NTP Radioisotopes Radioisotopes in Medicine Company Information
- 4.8.2 NTP Radioisotopes Radioisotopes in Medicine Business Overview
- 4.8.3 NTP Radioisotopes Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 NTP Radioisotopes Product Portfolio
- 4.8.5 NTP Radioisotopes Recent Developments
- 4.9 Polatom
- 4.9.1 Polatom Radioisotopes in Medicine Company Information
- 4.9.2 Polatom Radioisotopes in Medicine Business Overview
- 4.9.3 Polatom Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 Polatom Product Portfolio
- 4.9.5 Polatom Recent Developments
- 4.10 Rosatom
- 4.10.1 Rosatom Radioisotopes in Medicine Company Information
- 4.10.2 Rosatom Radioisotopes in Medicine Business Overview
- 4.10.3 Rosatom Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.10.4 Rosatom Product Portfolio
- 4.10.5 Rosatom Recent Developments
- 4.11 SHINE Technologies
- 4.11.1 SHINE Technologies Radioisotopes in Medicine Company Information
- 4.11.2 SHINE Technologies Radioisotopes in Medicine Business Overview
- 4.11.3 SHINE Technologies Radioisotopes in Medicine Production Capacity, Value and Gross Margin (2021-2026)
- 4.11.4 SHINE Technologies Product Portfolio
- 4.11.5 SHINE Technologies Recent Developments
5 Global Radioisotopes in Medicine Production by Region
- 5.1 Global Radioisotopes in Medicine Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Radioisotopes in Medicine Production by Region: 2021-2032
- 5.2.1 Global Radioisotopes in Medicine Production by Region: 2021-2026
- 5.2.2 Global Radioisotopes in Medicine Production Forecast by Region (2027-2032)
- 5.3 Global Radioisotopes in Medicine Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Radioisotopes in Medicine Production Value by Region: 2021-2032
- 5.4.1 Global Radioisotopes in Medicine Production Value by Region: 2021-2026
- 5.4.2 Global Radioisotopes in Medicine Production Value Forecast by Region (2027-2032)
- 5.5 Global Radioisotopes in Medicine Market Price Analysis by Region (2021-2026)
- 5.6 Global Radioisotopes in Medicine Production and Value, YOY Growth
- 5.6.1 North America Radioisotopes in Medicine Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Radioisotopes in Medicine Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Radioisotopes in Medicine Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Radioisotopes in Medicine Production Value Estimates and Forecasts (2021-2032)
6 Global Radioisotopes in Medicine Consumption by Region
- 6.1 Global Radioisotopes in Medicine Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Radioisotopes in Medicine Consumption by Region (2021-2032)
- 6.2.1 Global Radioisotopes in Medicine Consumption by Region: 2021-2026
- 6.2.2 Global Radioisotopes in Medicine Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Radioisotopes in Medicine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Radioisotopes in Medicine Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Radioisotopes in Medicine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Radioisotopes in Medicine Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Radioisotopes in Medicine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Radioisotopes in Medicine Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Radioisotopes in Medicine Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Radioisotopes in Medicine Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Radioisotopes in Medicine Production by Type (2021-2032)
- 7.1.1 Global Radioisotopes in Medicine Production by Type (2021-2032) & (t)
- 7.1.2 Global Radioisotopes in Medicine Production Market Share by Type (2021-2032)
- 7.2 Global Radioisotopes in Medicine Production Value by Type (2021-2032)
- 7.2.1 Global Radioisotopes in Medicine Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Radioisotopes in Medicine Production Value Market Share by Type (2021-2032)
- 7.3 Global Radioisotopes in Medicine Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Radioisotopes in Medicine Production by Application (2021-2032)
- 8.1.1 Global Radioisotopes in Medicine Production by Application (2021-2032) & (t)
- 8.1.2 Global Radioisotopes in Medicine Production Market Share by Application (2021-2032)
- 8.2 Global Radioisotopes in Medicine Production Value by Application (2021-2032)
- 8.2.1 Global Radioisotopes in Medicine Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Radioisotopes in Medicine Production Value Market Share by Application (2021-2032)
- 8.3 Global Radioisotopes in Medicine Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Radioisotopes in Medicine Value Chain Analysis
- 9.1.1 Radioisotopes in Medicine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Radioisotopes in Medicine Production Mode & Process
- 9.2 Radioisotopes in Medicine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Radioisotopes in Medicine Distributors
- 9.2.3 Radioisotopes in Medicine Customers
10 Global Radioisotopes in Medicine Analyzing Market Dynamics
- 10.1 Radioisotopes in Medicine Industry Trends
- 10.2 Radioisotopes in Medicine Industry Drivers
- 10.3 Radioisotopes in Medicine Industry Opportunities and Challenges
- 10.4 Radioisotopes in Medicine Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst